Physician profile
Mohammad A Wehbi
NPI 1952345258
$3,300.81
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $1,855.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $1,250.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.27 | 2019-2020 | |
| Abbvie INC. | $345.92 | 2019-2020 | |
| Medtronic USA, INC. | $315.75 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.80 | 2019-2020 | |
| Pfizer INC. | $146.29 | 2019 | |
| Merck Sharp & Dohme LLC | $139.44 | 2019-2020 | |
| Csa Medical, INC | $133.57 | 2019 | |
| Ironwood Pharmaceuticals, INC | $106.36 | 2019-2020 | |
| Dova Pharmaceuticals | $95.71 | 2019 | |
| Cook Medical LLC | $63.71 | 2019 | |
| Janssen Biotech, INC. | $48.18 | 2019-2020 | |
| Ethicon US, LLC | $30.84 | 2019-2020 | |
| Redhill Biopharma INC. | $25.13 | 2020 | |
| Intercept Pharmaceuticals, INC. | $23.85 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.71 | 2020 | |
| Daiichi Sankyo INC. | $16.35 | 2019 | |
| Ucb, INC. | $12.56 | 2020 | |
| Endo Pharmaceuticals INC. | $10.99 | 2020 | |
| Romark Laboratories, Lc | $10.38 | 2019-2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Wehbi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.